Verition Fund Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-17,989
| Closed | -$3.1M | – | 2165 |
|
|
2026
Q1 | $3.1M | Buy |
17,989
+8,484
| +89% | +$1.57M | 0.02% | 783 |
|
|
2025
Q4 | $1.9M | Sell |
9,505
-201
| -2% | -$36.5K | 0.01% | 1656 |
|
|
2025
Q3 | $1.52M | Sell |
9,706
-20,345
| -68% | -$3.23M | 0.01% | 2202 |
|
|
2025
Q2 | $4.56M | Buy |
30,051
+22,940
| +323% | +$3.06M | 0.02% | 1221 |
|
|
2025
Q1 | $1.07M | Sell |
7,111
-7,268
| -51% | -$1.22M | 0.01% | 2076 |
|
|
2024
Q4 | $2.65M | Buy |
+14,379
| New | +$2.77M | 0.01% | 1370 |
|
|
2024
Q3 | – | Sell |
-1,141
| Closed | -$236K | – | 3245 |
|
|
2024
Q2 | $236K | Buy |
+1,141
| New | +$259K | ﹤0.01% | 2496 |
|
|
2023
Q1 | – | Sell |
-1,629
| Closed | -$355K | – | 2214 |
|
|
2022
Q4 | $355K | Sell |
1,629
-318
| -16% | -$69.4K | 0.01% | 1412 |
|
|
2022
Q3 | $383K | Sell |
1,947
-505
| -21% | -$109K | ﹤0.01% | 2060 |
|
|
2022
Q2 | $525K | Buy |
+2,452
| New | +$599K | 0.01% | 1418 |
|
|
2020
Q4 | – | Sell |
-1,919
| Closed | -$435K | – | 1151 |
|
|
2020
Q3 | $435K | Sell |
1,919
-3,469
| -64% | -$720K | 0.01% | 623 |
|
|
2020
Q2 | $939K | Buy |
+5,388
| New | +$860K | 0.03% | 430 |
|
|
2019
Q4 | – | Sell |
-1,540
| Closed | -$204K | – | 1117 |
|
|
2019
Q3 | $204K | Buy |
+1,540
| New | +$206K | 0.01% | 946 |
|
|
2019
Q2 | – | Sell |
-3,762
| Closed | -$546K | – | 1114 |
|
|
2019
Q1 | $546K | Sell |
3,762
-2,887
| -43% | -$379K | 0.02% | 622 |
|
|
2018
Q4 | $753K | Buy |
6,649
+1,518
| +30% | +$190K | 0.05% | 324 |
|
|
2018
Q3 | $690K | Buy |
+5,131
| New | +$633K | 0.02% | 711 |
|
|
2018
Q2 | – | Sell |
-2,298
| Closed | -$245K | – | 1121 |
|
|
2018
Q1 | $245K | Buy |
+2,298
| New | +$248K | 0.02% | 910 |
|
|
2017
Q2 | – | Sell |
-6,495
| Closed | -$584K | – | 979 |
|
|
2017
Q1 | $584K | Buy |
6,495
+3,124
| +93% | +$265K | 0.05% | 484 |
|
|
2016
Q4 | $257K | Buy |
3,371
+334
| +11% | +$25.4K | 0.02% | 910 |
|
|
2016
Q3 | $253K | Buy |
+3,037
| New | +$255K | 0.03% | 869 |
|
|
2016
Q1 | – | Sell |
-12,592
| Closed | -$1.01M | – | 718 |
|
|
2015
Q4 | $1.01M | Buy |
+12,592
| New | +$908K | 0.19% | 101 |
|
|
2015
Q3 | – | Sell |
-3,697
| Closed | -$260K | – | 556 |
|
|
2015
Q2 | $260K | Sell |
3,697
-820
| -18% | -$60.7K | 0.05% | 361 |
|
|
2015
Q1 | $358K | Buy |
+4,517
| New | +$333K | 0.04% | 154 |
|
Other funds holding CRL
AI
Verition Fund Management's CRL Position: Q2 2026 in Review
Verition Fund Management sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 17,989 shares — an estimated $3.1M sold.
Verition Fund Management first reported a position in CRL in Q1 2015 and held it in 23 quarters. The position peaked at $4.56M in Q2 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Verition Fund Management reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
- Verition Fund Management sold 17,989 Charles River Laboratories shares in Q2 2026, an estimated $3.1M.
- Verition Fund Management first reported a position in Charles River Laboratories in Q1 2015 and held it in 23 quarters.
- Verition Fund Management's Charles River Laboratories position peaked at $4.56M in Q2 2025.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.